Acadia Healthcare Company, Inc. ACHC

Zacks Investment Research 13 nov

IQVIA Holdings (IQV) reported solid Q3 2026 results with R&D Solutions revenues up 8.7% year-over-year and net new bookings growing 15%, while Commercial Solutions revenues grew 6.9%. The company's deployment of 415 AI agents has improved operational efficiency, with adjusted EBITDA rising 8.7% and margins expanding by 20 basis points. Despite strong performance, IQV holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research 10 nov

Acadia Healthcare (ACHC) is highlighted as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and Momentum Style Score of B. The stock has significantly outperformed its industry and the broader market, rising 23.5% over the past week, 28.7% over the past quarter, and 112.49% over the past year. Positive earnings estimate revisions over the past two months support the bullish outlook.

Zacks Investment Research 4 nov

Acadia Healthcare reported Q3 2026 earnings of $0.60 per share, beating consensus estimates of $0.46, with revenues of $895.31 million exceeding expectations by 3%. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. The Medical-Hospital industry ranks in the bottom 7% of Zacks industries, which could limit future stock performance despite the company's strong year-to-date gains of 108.7%.

Zacks Investment Research 30 oct

Edwards Lifesciences is expected to report Q3 2026 results on November 4 with revenues of $1.68 billion (+8% YoY) and EPS of 73 cents (+9% YoY). The company's TAVR segment is projected to grow 35% YoY driven by procedural growth and new clinical approvals, while TMTT is expected to grow 5.1% YoY. Edwards has a positive Earnings ESP of +0.76% and Zacks Rank #3, suggesting potential for beating estimates.

Zacks Investment Research 28 oct

Envista is set to report Q3 2026 results on November 4, with consensus estimates expecting EPS to rise 9.4% to 35 cents and revenues to grow 2.5% to $686.3 million. The company is expected to benefit from strong Spark aligner demand, orthodontic expansion, stable implant sales, new consumables launches (ZenSeal Pro and DemiPro), and manufacturing efficiencies. However, the stock carries a negative Earnings ESP of -0.48% and a Zacks Rank #3, suggesting lower probability of beating estimates.